



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

March 14, 2016

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001

The Manager  
Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

Dear Sirs,

**Sub: Interim Injunction on the prohibition of the manufacture and sale of "Corex"**

We refer to our letter dated March 14, 2016 intimating the prohibition on sale of drug "Chlopheniramine Maleate + Codeine Syrup".

The Company has challenged the Notification No. S.O.909(E) dated March 10, 2016 before the Hon'ble Delhi High Court. We hereby inform you that the Hon'ble Delhi High Court was pleased to grant an interim injunction suspending the operation of the said notification banning the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup till the next date of hearing. The Order from the Hon'ble Delhi High Court in this respect is awaited.

Corex has a well-established efficacy and safety profile in India for more than 30 years and has both Central and State licenses and approvals. Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex.

We request you to kindly take the above on record.

Thanking you,

Yours truly,  
**For Pfizer Limited**

**Prajeet Nair**  
**Company Secretary**